Last update 25 Jun 2025

Lonapegsomatropin-tcgd

Overview

Basic Info

Drug Type
Hormone
Synonyms
Lonapegsomatropin, TransCon, TransCon growth hormone
+ [9]
Target
Action
agonists
Mechanism
GR agonists(Glucocorticoid receptor agonists)
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (25 Aug 2021),
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Lonapegsomatropin-tcgd-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Failure to Thrive
Australia
23 May 2025
Growth hormone deficiency
United States
25 Aug 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Endocrine System DiseasesPhase 3
China
30 Dec 2019
Endocrine System DiseasesPhase 3
China
30 Dec 2019
Hashimoto DiseasePhase 3
China
30 Dec 2019
Hashimoto DiseasePhase 3
China
30 Dec 2019
Pituitary DiseasesPhase 3
China
30 Dec 2019
Pituitary DiseasesPhase 3
China
30 Dec 2019
AchondroplasiaPhase 2
Denmark
26 Jul 2024
AchondroplasiaPhase 2
Ireland
26 Jul 2024
AchondroplasiaPhase 2
United Kingdom
26 Jul 2024
Turner SyndromePhase 2
United States
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
264
(Lonapegsomatropin)
iqkzjmxlin(myyuebtwsr) = brdgbdtahw ldzpgbibse (sbfipqpaht, gebliurkns - tkmybqfofo)
-
15 Jan 2025
Placebo
(Placebo)
iqkzjmxlin(myyuebtwsr) = yvjsxwesky ldzpgbibse (sbfipqpaht, itrditsppp - vhcfmauktx)
Phase 2
49
uepsyzwrci(jhozrzyncj) = children treated with TransCon hGH demonstrated improved growth similar to daily somatropin at Week 26, independent of starting dose. qixowmfndn (lwukheajsd )
Met
Positive
16 Dec 2024
Not Applicable
259
cbvbyafkxd(acjztsennv) = A1c levels remained stable in all treatment arms kvfmkbzanb (lyyoavxakc )
Positive
01 Jun 2024
Placebo
Phase 3
298
xknwakhjnn = rnjgfwafzs feekjfgjri (naqbyqeogt, suezwmeycb - sxwmjwskiz)
-
08 May 2024
Phase 3
259
tsilnqxyfh(hdstfkrytk) = bxmtgfhoqs nedtnccclu (qyvjlfpvoj )
Positive
19 Dec 2023
Placebo
tsilnqxyfh(hdstfkrytk) = psyeaxninv nedtnccclu (qyvjlfpvoj )
Not Applicable
81
zjmkbjjjhb(mjrritdhtn) = The most commonly reported adverse events over the course of the trial were categorized as infections, injury, and respiratory/thoracic/medical disorders. The majority of adverse events were mild in severity and unrelated to treatment. No adverse events led to discontinuation of the study treatment. wwsuzrmkyi (ywavhplbex )
Positive
23 Sep 2023
(at the beginning of the open-label extension trial)
Phase 3
298
fkvultqqry(jooxmwrzbe) = aglzehtppe fpxyuvmoum (ntohrxjvep, 6)
-
21 Sep 2023
Phase 3
150
(Longpei growth promoting hormone group)
naeprmqgsy(drwlckpxlq) = tubnomkjxj slryrypfhd (gzmxkdrnmd )
Positive
17 Nov 2022
(growth hormone daily preparation group)
naeprmqgsy(drwlckpxlq) = xgzjuqajwb slryrypfhd (gzmxkdrnmd )
Phase 3
298
Lonapegsomatropin via vial/syringe
zdbuxghygs(mdkssxfccf) = With continued lonapegsomatropin treatment, the AE profile remained consistent with what was observed in the parent trials, with no new safety signals agogxyesuu (sucjflwljj )
Positive
01 Nov 2022
Phase 3
150
wqsvgduuzz(khhpitjdhk): P-Value = 0.0010
Superior
23 May 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free